Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Batchelor

Showing results (291-300 of 321) with videos related to

Pageof 33
Sort By:
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Blood|March 18, 2021
A rapid genotyping panel for detection of primary central nervous system lymphomaMihir Gupta, Evan J Burns, Nicholas Z Georgantas, et al.
Cancer Cell|April 24, 2018
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor MicroenvironmentAmelie Griveau, Giorgio Seano, Samuel J Shelton, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Cancer Research|October 17, 2020
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System LymphomaKensuke Tateishi, Yohei Miyake, Masahito Kawazu, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2019
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial TumorsKensuke Tateishi, Taishi Nakamura, Tareq A Juratli, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Neuro-Oncology|February 8, 2017
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomasGanesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Pageof 33

Showing results (291-300 of 321) with videos related to

Sort By:
Pageof 33
Cancer Cell|December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ DepletionKensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Blood|March 18, 2021
A rapid genotyping panel for detection of primary central nervous system lymphomaMihir Gupta, Evan J Burns, Nicholas Z Georgantas, et al.
Cancer Cell|April 24, 2018
A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor MicroenvironmentAmelie Griveau, Giorgio Seano, Samuel J Shelton, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Cancer Research|October 17, 2020
A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System LymphomaKensuke Tateishi, Yohei Miyake, Masahito Kawazu, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2019
PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial TumorsKensuke Tateishi, Taishi Nakamura, Tareq A Juratli, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Neuro-Oncology|February 8, 2017
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomasGanesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, et al.
Nature Medicine|June 3, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosisPriscilla K Brastianos, Eudocia Quant Lee, Justine V Cohen, et al.
Pageof 33